JAK2 and non-small cell lung carcinoma: Additionally, Liao et al. indicate that ARL4C plays an important role in the resistance of non-small cell lung cancer (NSCLC) cells to Erlotinib, and the regulation of the drug resistance of lung cancer cells by ARL4C was through activating the β-catenin/JAK2/STAT5A signaling pathway (Liao et al., 2020).